Lexaria Bioscience Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lexaria Bioscience Corp. (NasdaqCM: LEXX) develops and licenses DehydraTECH, a proprietary drug delivery platform technology that enhances oral absorption of active pharmaceutical ingredients into the bloodstream for improved bioavailability, faster onset, and often reduced side effects; the technology applies to diverse molecules including GLP-1 and GIP drugs for diabetes and weight loss, cannabinoids such as CBD and THC, nicotine and analogs, vitamins, hormones, PDE5 inhibitors, antivirals, pain medications, antihypertensives, and other small and large therapeutics across indications like hypertension, heart disease, seizure disorders, neurology, oncology, and pain management; DehydraTECH supports multiple formats including tablets, capsules, oral suspensions, powders, beverages, foods, creams, lotions, and skin patches for pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. Founded in 2004 and headquartered at 740 McCurdy Road, Suite 100, Kelowna, British Columbia, Canada, with U.S. operations in Phoenix, Arizona, the company generates revenue through intellectual property licensing, B2B production, research and development, and corporate activities primarily in the United States and Canada. In recent developments, Lexaria closed a $4.0 million registered direct equity offering in September 2025 to fund R&D expansion through 2026, engaged a global life sciences advisory firm in October 2025 to pursue pharmaceutical and biotechnology partnerships targeting diabetes, hypertension, seizure disorders, and antivirals, received four new patents to bolster its portfolio of 54 granted patents worldwide, completed a Phase 1b human clinical trial on DehydraTECH-enabled CBD for hypertension in 2023, and underwent a leadership transition in October 2024 with Chris Bunka moving to Board Chairman and Anthony Moretti appointed CEO.
Lexaria Updates Business Development
Lexaria Updates Business Development
Lexaria's Human Study GLP-1-H26-7 has Begun Dosing on Schedule
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Lexaria's Animal Study GLP-1-A26-1 has Begun Dosing on Schedule
GLP-1 "Arms Race" Intensifies as the Addressable Markets Continue to Expand
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway.
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Lexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Updates Progress on Human Study #7
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended